Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health is viewed favorably because its Performance Suite business is showing strong demand and improving visibility, anchored by the addition of the $300 million oncology contract, the full-year contribution from Highmark, and the ramp of other signed agreements that support roughly 25% revenue growth in 2027. Fundamentally, the company’s outlook is reinforced by rising adjusted EBITDA estimates to $129 million in 2026 and $151 million in 2027, with management and the analyst noting that the 2027 EBITDA midpoint of about $150 million is increasingly derisked as medical cost trends improve and first-year downside protection on new contracts reduces launch pressure. Although Technology & Services is expected to decline by about 11%-12% because of membership attrition, Medicaid work requirements, and pricing pressure, the market leadership in specialty value-based care, improving contract economics, and expected margin improvement in Performance Suite provide a stronger earnings trajectory and a positive risk/reward setup.

Evolent Health is facing a fundamentally fragile outlook because its business remains exposed to HCIT industry risks such as slower government-driven spending, constrained hospital budgets, customer losses from consolidation, and intensifying price competition, all of which can pressure demand for its services and delay non-EHR purchasing decisions. The company’s own guidance commentary suggests that the larger step-up in 2026 revenue is being driven less by organic momentum and more by contractual capitation adjustments tied to disease-prevalence changes, while the expected 2027 adjusted EBITDA midpoint of about $150 million already absorbs reserve and profitability pressure from the roughly $300 million oncology launch and potential new Performance Suite contracts. Although claims performance at Aetna has looked good and oncology trend is favorable versus last year, the model still relies on payor rate adjustments materializing to offset utilization risk and on new contract wins and margin maturation progressing as expected, leaving meaningful downside if those supports do not come through.